Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

Flores E, Santos-Gallego CG, Diaz-Mejía N, Badimon JJ.

Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222. doi: 10.1007/s10557-018-6786-x. Review.

PMID:
29679303
2.

2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.

Chiang CE, Lin SY, Lin TH, Wang TD, Yeh HI, Chen JF, Tsai CT, Hung YJ, Li YH, Liu PY, Chang KC, Wang KL, Chao TH, Shyu KG, Yang WS, Ueng KC, Chu PH, Yin WH, Wu YW, Cheng HM, Shin SJ, Huang CN, Chuang LM, Lin SJ, Yeh SJ, Sheu WH, Lin JL.

J Chin Med Assoc. 2018 Mar;81(3):189-222. doi: 10.1016/j.jcma.2018.01.001. Epub 2018 Feb 13.

3.

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.

Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC.

BMJ. 2018 Feb 6;360:k119. doi: 10.1136/bmj.k119.

4.

Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.

Guo WQ, Li L, Su Q, Dai WR, Ye ZL.

Value Health. 2017 Dec;20(10):1427-1430. doi: 10.1016/j.jval.2017.04.010. Epub 2017 May 29.

5.

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI.

Circulation. 2017 Oct 24;136(17):1643-1658. doi: 10.1161/CIRCULATIONAHA.117.030012. Review.

6.

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E.

Cardiovasc Diabetol. 2017 Sep 11;16(1):112. doi: 10.1186/s12933-017-0593-8.

7.

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.

Brown AJM, Lang C, McCrimmon R, Struthers A.

BMC Cardiovasc Disord. 2017 Aug 23;17(1):229. doi: 10.1186/s12872-017-0663-6.

8.

EMPA-REG OUTCOME: The Endocrinologist's Point of View.

Perreault L.

Am J Cardiol. 2017 Jul 1;120(1S):S48-S52. doi: 10.1016/j.amjcard.2017.05.010. Epub 2017 May 17. Review.

9.

EMPA-REG OUTCOME: The Endocrinologist's Point of View.

Perreault L.

Am J Med. 2017 Jun;130(6S):S51-S56. doi: 10.1016/j.amjmed.2017.04.005.

10.

GLP-1 receptor agonists and heart failure in diabetes.

Scheen AJ.

Diabetes Metab. 2017 Apr;43 Suppl 1:2S13-2S19. doi: 10.1016/S1262-3636(17)30068-X. Review.

11.

Treatment Deintensification Is Uncommon in Adults With Type 2 Diabetes Mellitus: A Retrospective Cohort Study.

McAlister FA, Youngson E, Eurich DT.

Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). pii: e003514. doi: 10.1161/CIRCOUTCOMES.116.003514.

PMID:
28416531
12.

Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.

Tanaka A, Node K.

J Cardiol. 2017 Mar;69(3):501-507. doi: 10.1016/j.jjcc.2016.10.019. Epub 2016 Dec 30. Review.

13.

Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.

Coch RW, Green JB.

Nutr Metab Cardiovasc Dis. 2016 Sep;26(9):767-72. doi: 10.1016/j.numecd.2016.06.004. Epub 2016 Jun 16. Review.

PMID:
27378397
14.

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.

Levine MJ.

Curr Diabetes Rev. 2017;13(4):405-423. doi: 10.2174/1573399812666160613113556. Review.

15.

Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.

Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S.

Diabetes Obes Metab. 2016 Oct;18(10):990-8. doi: 10.1111/dom.12704. Epub 2016 Jul 19.

PMID:
27282621
16.

Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.

Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I.

Heart. 2016 Oct 1;102(19):1581-7. doi: 10.1136/heartjnl-2015-309164. Epub 2016 May 23.

17.

DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.

Bonora E, Cigolini M.

Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):273-84. doi: 10.1016/j.numecd.2016.03.002. Epub 2016 Mar 12. Review.

PMID:
27038847
18.

Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.

Steinberg HO.

Postgrad Med. 2016 May;128(4):398-408. doi: 10.1080/00325481.2016.1168687. Epub 2016 Apr 7. Review.

PMID:
26999348
19.

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Fisman EZ, Tenenbaum A.

Cardiovasc Diabetol. 2015 Sep 29;14:129. doi: 10.1186/s12933-015-0294-0. Review.

20.

Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.

Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS.

J Diabetes. 2016 Mar;8(2):279-85. doi: 10.1111/1753-0407.12301. Epub 2015 Jun 29.

PMID:
25929426

Supplemental Content

Loading ...
Support Center